David N. Standring

4.6k total citations · 1 hit paper
59 papers, 3.7k citations indexed

About

David N. Standring is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, David N. Standring has authored 59 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Epidemiology, 32 papers in Hepatology and 22 papers in Infectious Diseases. Recurrent topics in David N. Standring's work include Hepatitis B Virus Studies (34 papers), Hepatitis C virus research (32 papers) and HIV/AIDS drug development and treatment (16 papers). David N. Standring is often cited by papers focused on Hepatitis B Virus Studies (34 papers), Hepatitis C virus research (32 papers) and HIV/AIDS drug development and treatment (16 papers). David N. Standring collaborates with scholars based in United States, France and Germany. David N. Standring's co-authors include William J. Rutter, Maria Seifer, Sen Zhou, Jeremy R. Knowles, Hagan Bayley, Victor A. Fried, Richard A. Roth, Michèle C. Smith, Jeffrey C. Edman and David O. Morgan and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Molecular and Cellular Biology.

In The Last Decade

David N. Standring

59 papers receiving 3.5k citations

Hit Papers

Insulin-like growth factor II receptor as a multifunction... 1987 2026 2000 2013 1987 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Insulin-like growth factor II receptor as a multifunctional binding protein
    1987 727 citations David N. Standring, William J. Rutter et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David N. Standring United States 30 1.8k 1.4k 1.3k 834 450 59 3.7k
Michael G. Cordingley Canada 33 1.0k 0.6× 1.5k 1.1× 325 0.2× 385 0.5× 277 0.6× 56 3.2k
Lisette Lagacé Canada 25 553 0.3× 852 0.6× 354 0.3× 282 0.3× 139 0.3× 49 2.2k
Robert Hamatake United States 33 955 0.5× 1.6k 1.1× 765 0.6× 593 0.7× 397 0.9× 76 3.1k
Mark A. Feitelson United States 41 3.5k 1.9× 2.6k 1.9× 2.1k 1.6× 399 0.5× 53 0.1× 124 6.2k
Ganjam V. Kalpana United States 33 1.2k 0.6× 4.0k 2.9× 300 0.2× 1.6k 1.9× 61 0.1× 64 6.0k
D W McCourt United States 28 894 0.5× 1.2k 0.9× 1.1k 0.8× 537 0.6× 141 0.3× 41 3.4k
Craig S. Gibbs United States 36 2.7k 1.5× 1.3k 0.9× 2.5k 1.9× 1.2k 1.4× 79 0.2× 66 4.7k
Richard J. Stockert United States 36 527 0.3× 2.3k 1.6× 582 0.4× 148 0.2× 294 0.7× 91 4.4k
Katsuro Koike Japan 31 1.9k 1.1× 1.3k 1.0× 1.1k 0.9× 259 0.3× 30 0.1× 89 3.0k
Lenora J. Davis United States 18 190 0.1× 2.1k 1.5× 237 0.2× 1.0k 1.2× 238 0.5× 24 3.7k

Countries citing papers authored by David N. Standring

Since Specialization
Citations

This map shows the geographic impact of David N. Standring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Standring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Standring more than expected).

Fields of papers citing papers by David N. Standring

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Standring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Standring. The network helps show where David N. Standring may publish in the future.

Co-authorship network of co-authors of David N. Standring

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Standring. A scholar is included among the top collaborators of David N. Standring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Standring. David N. Standring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rush, Roger, et al.. (2015). Single- and repeat-dose toxicity of IDX14184, a nucleotide prodrug with antiviral activity for hepatitis C viral infection, in mice, rats, and monkeys. Human & Experimental Toxicology. 35(5). 472–490. 6 indexed citations
2.
Alexandre, François-René, Catherine Caillet, Thierry Convard, et al.. (2015). Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease. Bioorganic & Medicinal Chemistry Letters. 25(18). 3984–3991. 8 indexed citations
3.
McCarville, Joseph, Maria Seifer, David N. Standring, & Douglas L. Mayers. (2013). 1209 TREATMENT-EMERGENT VARIANTS FOLLOWING 3 DAYS OF MONOTHERAPY WITH IDX719, A POTENT, PAN-GENOTYPIC NS5A INHIBITOR, IN SUBJECTS INFECTED WITH HCV GENOTYPES 1–4. Journal of Hepatology. 58. S491–S492. 4 indexed citations
4.
Dousson, Cyril B., Christopher Chapron, David N. Standring, et al.. (2011). 815 IDENIX NS5A HCV REPLICATION INHIBITORS WITH LOW PICOMOLAR, PAN-GENOTYPIC IN VITRO ANTIVIRAL ACTIVITY. Journal of Hepatology. 54. S326–S327. 7 indexed citations
5.
Bilello, John P., et al.. (2010). 769 A TRIPLE COMBINATION OF DIRECT-ACTING ANTIVIRAL AGENTS DEMONSTRATES ROBUST ANTI-HCV ACTIVITY IN VITRO. Journal of Hepatology. 52. S299–S299. 3 indexed citations
6.
Alexandre, François-René, Agnès Amador, Catherine Caillet, et al.. (2010). Synthesis and Biological Evaluation of Aryl-phospho-indole as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry. 54(1). 392–395. 152 indexed citations
7.
Bilello, John P., Massimiliano La Colla, Michel Liuzzi, et al.. (2009). 344 PRECLINICAL PROFILES OF IDX136 AND IDX316, TWO NOVEL MACROCYCLIC HCV PROTEASE INHIBITORS. Journal of Hepatology. 50. S132–S132. 1 indexed citations
8.
9.
Standring, David N., Margareta Larsson, Claire Pierra, et al.. (2008). 67 POTENT ANTIVIRAL ACTIVITY OF SECOND GENERATION NUCLEOSIDE INHIBITORS, IDX102 AND IDX184, IN HCV-INFECTED CHIMPANZEES. Journal of Hepatology. 48. S30–S30. 16 indexed citations
10.
11.
12.
Pierra, Claire, S. Benzaria, David Dukhan, et al.. (2004). Synthesis, Physicochemical and Pharmacokinetic Studies of Potential Prodrugs of β-L-2′-Deoxycytidine, a Selective and Specific Anti-HBV Agent. Antiviral chemistry & chemotherapy. 15(5). 269–279. 3 indexed citations
13.
Benzaria, S., Claire Pierra, Dorothée Bardiot, et al.. (2003). Monoval-LdC: Efficient Prodrug of 2′-Deoxy-β-L-cytidine (L-dC), A Potent and Selective Anti-HBV Agent. Nucleosides Nucleotides & Nucleic Acids. 22(5-8). 1003–1006. 3 indexed citations
14.
Butkiewicz, Nancy, Nanhua Yao, Weidong Zhong, et al.. (2000). Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3. Journal of Virology. 74(9). 4291–4301. 36 indexed citations
15.
Hamatake, Robert, Marc Bifano, Dennis Hernandez, et al.. (1996). Establishment of an in vitro Assay to Characterize Hepatitis C Virus NS3-4A Protease <i>Trans</i>-Processing Activity. Intervirology. 39(4). 249–258. 7 indexed citations
16.
Seifer, Maria & David N. Standring. (1995). Ribonucleoprotein Complex Formation by the Human Hepatitis B Virus Polymerase. Intervirology. 38(5). 295–303. 3 indexed citations
17.
Seifer, Maria & David N. Standring. (1995). Assembly and Antigenicity of Hepatitis B Virus Core Particles. Intervirology. 38(1-2). 47–62. 36 indexed citations
18.
Seifer, Maria & David N. Standring. (1993). Stability Governs the Apparent Expression of "Particulate" Hepatitis B e Antigen by Mutant Hepatitis B Virus Core Particles. Virology. 196(1). 70–78. 9 indexed citations
19.
Standring, David N., J H Ou, & William J. Rutter. (1986). Assembly of viral particles in Xenopus oocytes: pre-surface-antigens regulate secretion of the hepatitis B viral surface envelope particle.. Proceedings of the National Academy of Sciences. 83(24). 9338–9342. 85 indexed citations
20.
Standring, David N., Leslie B. Rall, Orgad Laub, & William J. Rutter. (1983). Hepatitis B Virus Encodes an RNA Polymerase III Transcript. Molecular and Cellular Biology. 3(10). 1774–1782. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael G. Cordingley Breakdown of academic impact, for papers by Lisette Lagacé Breakdown of academic impact, for papers by Robert Hamatake Breakdown of academic impact, for papers by Mark A. Feitelson Breakdown of academic impact, for papers by Ganjam V. Kalpana Breakdown of academic impact, for papers by D W McCourt Breakdown of academic impact, for papers by Craig S. Gibbs Breakdown of academic impact, for papers by Richard J. Stockert Breakdown of academic impact, for papers by Katsuro Koike Breakdown of academic impact, for papers by Lenora J. Davis
Rankless by CCL
2026